Introduction
Familial Mediterranean fever (OMIM 249100) is a genetic disease inherited as autosomal recessive trait, characterized by recurrent, self-limited attacks of fever with serositis involving the peritoneum, pleura and joints [1, 2] . The disease is caused by mutations in the MEFV gene located on chromosome 16 and primarily affects populations surrounding the Mediterranean basin, mainly Sephardic and Ashkenazi Jews, Armenians, Turks and Arabs [3, 4] . Although attacks are self-limited, some patients develop amyloidosis leading to renal failure [5] . Daily colchicine treatment is frequently an effective treatment for the prevention of Familial Mediterranean fever attacks and amyloidosis in compliant patients [2] .
Acute-phase reactants are usually elevated during the attacks of Familial Mediterranean fever and return to normal with clinical remission [6] . However, in some patients, acute-phase reactants can remain high during the intervals between the attacks [7, 8] . This has led to proposition that subclinical inflammation continues during the attack-free periods. Although the subclinical or chronic inflammation may have important clinical consequences, the clinical and genetic risk factors for ongoing inflammation have not been well characterized in children so far. In this study, we Abstract Familial Mediterranean fever (FMF) is the most common autosomal recessive inherited inflammatory disease characterized by attacks of painful inflammation. Some patients with FMF have subclinical inflammation persisting between the attacks. We aimed to identify the demographic, clinical and genetic risk factors for subclinical inflammation in children with FMF. The medical records of the children with FMF were evaluated retrospectively for acute-phase response along with gender, age at the onset of symptoms and at the time of diagnosis, clinical signs and symptoms, the presence of amyloidosis and MEFV genotype. Patients with persistently elevated acutephase response between the attacks were considered to have subclinical inflammation. Patients with or without subclinical inflammation (Group 1 and Group 2, respectively) were compared for the parameters defined above. Independent risk factors for subclinical inflammation were identified by multivariate logistic regression analysis. There were 105 children (male/female: 52/53) who were compliant on colchicine treatment. Subclinical inflammation was detected in 22 (20 %) patients. Group 1 had significantly higher rate of myalgia, arthritis/arthralgia, erysipelas like erythema, amyloidosis, protracted febrile myalgia and M694V mutation compared with Group 2. However, only the presence of myalgia and erysipelas like erythema were found to be independent risk factors for subclinical inflammation (OR examined clinical, demographic and genotypic features that might be associated with subclinical inflammation in children with Familial Mediterranean fever.
Patients and methods
We retrospectively reviewed the medical records of 105 children with Familial Mediterranean fever followed in the Pediatric Nephrology Department of Dokuz Eylül University School of Medicine in Izmir, which is the biggest city in western Anatolia. The diagnosis of Familial Mediterranean fever was established according to the Tel-Hashomer criteria [9] . Patients who have been regularly treated with colchicine for at least 6 months were included, while incompliant patients were excluded from the study.
Acute-phase reactants such as white blood cell count, erythrocyte sedimentation rate, and C-reactive protein and fibrinogen levels during the attacks and attack-free periods (at least 10 days after the attack) were noted from the patients' files. Attack-free periods were symptom free. Persistently, elevated values of at least one acute-phase reactants during attack-free period were interpreted as subclinical inflammation [7, 8] . The patients were grouped as those with or without subclinical inflammation (Group 1 and Group 2, respectively). Demographic (sex, age at diagnosis and at onset of symptoms), clinical (abdominal pain, fever, arthritis/arthralgia, myalgia, erysipelas like erythema, chest pain, amyloidosis, family history of Familial Mediterranean fever, response to colchicine treatment) and genotypic findings (MEFV gene mutation, specifically homozygosity or compound heterozygosity for M694V) were compared between these groups.
Myalgia was defined as pain or tenderness or both in the extremities away from the joints. Myalgia in children with FMF is common and can follow three different clinical patterns (the exercise-induced pattern, spontaneous pattern and protracted febrile myalgia syndrome) [10] . Spontaneous myalgia was defined as myalgia not related to any other precipitating factor. Exercise-induced myalgia was defined as the onset of myalgia within several hours of exercise. Protracted febrile myalgia was defined as severe crippling myalgia and high fever.
The study was approved by the local ethical committee of our institution. All patients signed the informed consent for participation in the study.
Mutation analysis
Genomic DNA was isolated from peripheral leukocytes, using the QIAamp DNA Blood Mini Kit (Qiagen) according to the manufacturers' instructions. Patients were studied using a reverse hybridization, test strip-based assay (Familial Mediterranean fever Strip Assay; Vienna Lab Labodiagnostika, Vienna, Austria) for the mutations. The first step consists of a multiplex polymerase chain reaction analysis using biotinylated primers for amplifying exons. Polymerase chain reaction products are then selectively hybridized to a test strip presenting a parallel array of allele-specific oligonucleotide probes. Hybridizations were illuminated by the reaction of streptavidin-alkaline phosphatase and a color substrate [11] .
Statistical analysis
In order to define risk factors for subclinical inflammation, multiple logistic regression analysis was used. Prior to logistic regression analysis, potential independent risk factors were determined by means of the appropriate statistical methods. The Chi-square test (or Fisher's exact test) was used for categorical variables. The numeric variables were compared with Mann-Whitney U test. After that, we designed multivariate logistic regression analyses to identify independent risk factors for subclinical inflammation. The variables that had a p value of <0.25 in the univariate analysis were considered as candidates for the multivariate logistic model. Odds ratios (ORs) with 95 % confidence intervals (95 % CIs) were calculated. A value of p < 0.05 was considered statistically significant. SPSS software (version 16.0, SPSS) was used for this statistical analysis.
Results

Demographic and clinical characteristics
The study population was composed of 105 children (male/ female: 52/53). Twenty-two (20 %) of these patients had subclinical inflammation. Demographic, clinical and genotypic features of the Group 1 and Group 2 are summarized in Tables 1 and 2 . Mean age at the time of study and mean age at disease onset were not different between Group 1 and Group 2. However, frequency of myalgia, arthritis/ arthralgia, erysipelas like erythema, protracted febrile myalgia and amyloidosis were higher in Group 1 than in Group 2.
Erysipelas like erythema was unrelated with longduration travel in our study population. Myalgia's pattern was spontaneous (not related to exercise or any other precipitating factor during acute attacks) or protracted febrile myalgia syndrome in our patients. All patients with myalgia without protracted febrile myalgia were non-crippling myalgia with pain or tenderness. In patients with protracted febrile myalgia, myalgia was in the style of severe crippling myalgia. In addition, the duration of myalgia was long term in patients with protracted febrile myalgia. However, the duration of myalgia in patients with spontaneous myalgia was short term, which was similar to the attack time. Protracted febrile myalgia and amyloidosis were present only in children with subclinical inflammation (six and two of these children had these findings, respectively). All children with protracted febrile myalgia had M694V mutation (three homozygotes, three heterozygotes). On the other hand, frequency of other clinical symptoms was not different between groups.
MEFV mutation analysis
Mutations in the MEFV gene were identified in 21 (95 %) and 69 (83 %) patients in Group 1 and Group 2 ( Table 2) . Frequency of single mutation or ≥2 mutations in MEFV gene was not different between the groups. However, frequency of two mutations in exon 10 of MEFV gene was higher in Group 1 compared with Group 2 (15/7 vs. 35/48, respectively). For M694V homozygotes or compound heterozygotes, this difference was more evident (50 vs. 18 %, p = 0.004 and 73 vs. 46 %, p = 0.021, respectively) ( Table 1) .
In subclinical inflammation group, paired MEFV mutations were identified in 16 patients (73 %). Fifteen (68 %) of these had two mutations in exon 10, including 11 who had M694V homozygote mutation, and four who had M694V compound heterozygote mutation. A single mutation was detected in five patients (23 %), and no mutation was found in only one case (4 %) ( Table 2) .
Independent risk factors affecting subclinical inflammation
In order to determine independent risk factors for subclinical inflammation in children with Familial Mediterranean fever, we performed multivariate logistic regression analyses. In the final model, as shown in Table 3 , increased risk of subclinical inflammation was observed in children who had myalgia (OR 9.78, 95 % CI 1.20-63.32) and erysipelas like erythema during attacks (OR 5.96, 95 % CI 1.09-32.41). The presence of arthritis/arthralgia during attacks and M694V homozygote/compound heterozygote mutations were not independent risk factors, although these parameters were significantly higher in Group 1 in univariate analyses.
Discussion
The levels of acute-phase reactants fall significantly after an acute Familial Mediterranean fever attack is over. However, various studies had shown that almost one-fourth to one-third of patients with Familial Mediterranean fever had higher than normal levels of acute-phase proteins [8, 12] . Moreover, over half of the patients had subclinical inflammation in studies including serum amyloid A measurements [13, 14] . Thus, a significant rate of patients with Familial Mediterranean fever had subclinical inflammation. Therefore, we aimed to identify risk factors for subclinical inflammation in childhood cases of Familial Mediterranean fever. 
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The results of our study indicate that at least 20 % of patients had higher than normal levels of acute-phase reactants. It was shown that at least one acute-phase reactant was above normal in 30-63 % of patients with Familial Mediterranean fever during attack-free periods [8, 12] . In one of these studies, 63 % of patients were determined to have increased levels of at least one acute-phase protein, while two or more acute-phase proteins were elevated in only 25 % of them [8] . In the other study, 31.4 % of patients had at least one increased acute-phase protein level [12] . These studies were prospectively designed. On the other hand, our study was retrospective, and thus, we might have missed some cases with subclinical inflammation. This might explain low rate of subclinical inflammation (20 %) in our study population, compared with the studies described above.
Our results indicate that frequency of myalgia, arthritis/arthralgia, erysipelas like erythema, protracted febrile myalgia during acute attacks and amyloidosis were higher in patients with subclinical inflammation than in other Familial Mediterranean fever patients. On the other hand, independent risk factors for subclinical inflammation in our total study population were myalgia and erysipelas like erythema. In the literature, there are few data associated with risk factors for ongoing inflammation in patients with Familial Mediterranean fever, but these factors are not well characterized. Nevertheless, it has been expressed that the MEFV genotype and compliance to colchicine treatment are the two factors most powerfully associated with the presence of subclinical inflammation [15] . On the other hand, miscellaneous risk factors for the development of amyloidosis such as male gender, age of disease onset, frequency of acute attacks, homozygosity for the isomer of serum amyloid A 1 and joint involvement during attacks could be also other predisposing factors for ongoing inflammation in patients with Familial Mediterranean fever [16] [17] [18] . However, these factors have not yet been examined.
In this study, we found that frequency of M694V homozygosity and compound heterozygosity were higher in patients with subclinical inflammation. However, multivariate logistic analysis did not show these mutations as independent risk factors. On the other hand, in a previous study, it was found that phenotype 3 cases (persons having ≥2 mutations, but no clinical disease) with M694V homozygote mutation had considerably higher serum amyloid A and C-reactive protein levels than persons who carried two other mutations [13] . Furthermore, in another study, it was determined that silent carries of M694V mutation had elevated levels of the acute-phase reactants compared with non-carrier relatives [7] . In addition, it was shown that patients who had M694V homozygote mutation had the highest levels of serum amyloid A during remission among a group patient with Familial Mediterranean fever [19] . Therefore, we consider M694V mutation as an important risk factor for subclinical inflammation, although it was not found to be an independent risk factor in our study.
Risk factors for amyloidosis in FMF include homozygosity for M694V mutation, non-regular use of colchicine, genetic background of patients, ethnicity, male gender, age of disease onset, frequency of acute attacks, homozygosity for the isomer of serum amyloid A1 and joint involvement during attacks. The most important factor in the development of amyloidosis is the increase in production of the SAA protein, which is synthesised in the liver. Increased synthesis of this insoluble protein, and hence decreased elimination of it, leads to accumulation of the molecule in extracellular areas and the development of amyloidosis [20] . In fact, more than half of FMF patients were determined to have subclinical inflammation when serum amyloid A levels were measured during asymptomatic periods [13, 14] . Thus, it would have been better if we had serum amyloid A measurements in our patients. However, as serum amyloid A levels are not measured in our laboratory, we could not evaluate the relation of serum amyloid A levels to subclinical inflammation in the present study. Therefore, actual number of patients with subclinical inflammation may be higher. Another limitation of our study is the small number of patient population which may have influenced the results especially in multivariate logistic regression.
Colchicine treatment can prevent or decrease the number and intensity of attacks and also prevents complications related with inflammation such as amyloidosis [21, 22] . Moreover, colchicine treatment decreases also levels of the markers of subclinical inflammation in asymptomatic or symptomatic patients [2, 14] . On the other hand, subclinical inflammation may continue in different degrees despite optimum colchicine treatment [7, 8, 13, 14] . This may result eventually in amyloidosis and other complications of persistent inflammation. We prescribed optimum dose of colchicine to all of our patients, and only compliant patients were enrolled in this study. Thus, we did not evaluate non-compliance with colchicine treatment as a risk factor.
Although Familial Mediterranean fever is typically characterized by attacks of painful serosal inflammation, this presentation symbolizes only the tip of the iceberg. Many patients with Familial Mediterranean fever have subclinical inflammation in attack-free periods. This subclinical inflammation may lead to some complications such as splenomegaly, normocytic-normochromic anemia, increased risk of heart disease, growth retardation in children, impaired quality of life, depression and anxiety, female infertility, preterm deliveries, decreased bone mineral density and amyloid A amyloidosis [15] . Some effects of this chronic inflammation can be more prominent in children because of the continuing growth. Therefore, children with Familial Mediterranean fever who particularly have myalgia, erysipelas like erythema or protracted febrile myalgia should be closely monitored for ongoing inflammation.
All of our patients had phenotype 1 disease (clinically overt disease). However, some patients of Familial Mediterranean fever have no clinical attacks, and persistent subclinical inflammation is the only proof of their disease. These persons are not aware of their disease, but still are at risk for the complications of Familial Mediterranean fever [23, 24] . These phenotype 2 patients present with amyloid A amyloidosis as the only manifestation of disease, and the diagnosis of Familial Mediterranean fever is based on family history of phenotype 1 disease or on the presence of MEFV mutations. Reactive amyloid A amyloidosis provides strong evidence for the presence of persistent long-term subclinical inflammation in phenotype 2 patients. Colchicine treatment decreases the rate of amyloidosis in these patients [25, 26] . Therefore, family members of patients with Familial Mediterranean fever or children with MEFV mutations should be intermittently examined for the presence of subclinical inflammation. If subclinical inflammation is determined, initiation of colchicine treatment may be appropriate.
Conclusion
Despite the progress in understanding the pathogenesis of inflammation in Familial Mediterranean fever, there are still many unresolved questions. One of these problems is the recognition of risk factors for subclinical inflammation. We identified several risk factors (myalgia, arthritis/arthralgia, erysipelas like erythema, amyloidosis, protracted febrile myalgia and M694V mutation) for subclinical inflammation in children, but only two of these were independent factors (myalgia and erysipelas like erythema). For the prevention of the long-term complications (growth retardation, anemia, decreased bone mineral density, etc.) with better control of subclinical inflammation, larger epidemiological and longitudinal studies are need for the identification of new risk factors for subclinical inflammation.
